SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$90.25
−2.62%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$93.69
From 52W high−17.14%
Volume3.35M
Market cap$7.96B
P/E (TTM)—
P/S (TTM)87.9x
Div yield—
Key dataSep 18, 2026
Open
$93.69
From 52W high
−17.14%
Volume
3.35M
Market cap
$7.96B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.5x
P/E (TTM)
—
RSI (14)
42.8
MomentumView details →
1D Return
−2.62%
YTD Return
+175.37%
SummaryUpdated Jun 1, 2026
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a preclinical-stage biotechnology company founded in 2013 and headquartered in Waltham, Massachusetts. The company went public in April 2016 and underwent a significant strategic transformation in November 2023, when it changed its name from Aeglea BioTherapeutics to Spyre Therapeutics to reflect its new focus on inflammatory bowel disease treatments. This pivot marked a complete shift from the company's previous focus on rare genetic diseases to developing novel antibody therapies for patients suffering from inflammatory bowel disease.
Similar companies
Latest newsMore news →
Spyre Therapeutics shares fell 12.35% in after-hours trading after its mid-stage clinical trial for a rheumatoid arthritis drug failed to meet internal criteria for advancing as a monotherapy.25d agoSpyre Therapeutics' Compensation Committee approved equity inducement awards of stock options for 19,436 shares and 6,186 restricted stock units to four non-executive employees on August 3, 2026, as material inducements to their employment acceptance.44d agoSpyre Therapeutics granted stock options and restricted stock units to six non-executive employees as inducement awards to accept employment.80d ago